Abstract Annexin A3 (ANXA3) is a member of the annexin family of calcium-dependent phospholipid-binding proteins and plays a major role in various membrane-related processes. ANXA3 expression was analyzed by immunohistochemistry (IHC) on tissue microarrays (TMAs) containing 17,285 samples from 148 different tumor types. ANXA3 staining was seen in 10,223 (75.9%) of the 13,472 interpretable tumors and was considered weak in 16.3%, moderate in 10.1%, and strong in 49.4% of cases.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ronald Simon
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
|
By Arsela Prelaj, Vanja Mišković, Matteo Antonio Sacco, Alberto Ferrarin, Leonardo Provenzano, Andrea Spagnoletti, Monica Ganzinelli, Daniele Lorenzini, Luca Invernizzi, Cecilia Silvestri, Laura Mazzeo, Marco Meazza Prina, Giulia Corrao, Andra Diana Dumitrascu, Dario Monzani, Gabriella Pravettoni, Chiara Cavalli, Rebecca Romano, Claudia Giani, Alessandra Esposito, Christine M. Bestvina, Maria Spector, Laila Roisman, Till Olchers, Heinz Richter, Anna Di Lello, Valentina Bartolomeo, Evangelos G Sarris, Elena Fountzilas, Aina Roca, Patricia Iranzo, Jose Rodríguez-Morató, Luca Agnelli, Mario Occhipinti, Marta Brambilla, Teresa Beninato, Claudia Proto, Eliana Rulli, Stefan Steurer, Ronald Simon, Michael Willis, Giancarlo Pruneri, Filippo de Braud, Marcello Restelli, Enriqueta Felip, Nir Peled, Alexander Pearson, Helena Linardou, Martin Reck, Giuseppe Lo Russo, Marina Chiara Garassino, Cristina Maria Licciardello, Margherita Favali, Ludovica Lerma, Aleksandra Zec, Beshoy Guirges, Margherita Ruggirello, Michele Zanitti, Davide Macocchi, Moreno Bruno Marino, Samuel G. Armato III, Bogot R. Naama, Reham Basheer, Adi Lahiani Hafzadi, Iris Watermann, Marlen Szewczyk, Constantin Blanke-Roeser, Costanza Siniscalchi, Teresa Arangoa, Nikolaos Spathas, Rocio Caro-Consuegra, Melissa Fernández-Pinto, Sokol Kosta, Francesco Trovò
|
Nature
Verified
Abstract Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I3LUNG (NCT05537922) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based study, enrolling 2,396 patients.
TROP2 Is Uniformly Expressed in Primary Prostate Cancer but Frequently Reduced in Recurrent Disease.
Background: TROP2 (TACSTD2) is a therapeutic target of antibody-drug conjugates and is broadly expressed in epithelial malignancies. Data on TROP2 protein expression in large, clinically annotated prostate cancer cohorts, particularly in recurrent disease, remain limited. Methods: TROP2 immunohistochemistry was performed on a prostate cancer tissue microarray comprising 17,747 primary radical prostatectomy specimens and 258 recurrent prostate cancer samples.
Beyond EML4 : efficacy of targeted therapy in lung cancer patients with rare ALK fusions – a real-world retrospective analysis
|
By Felix Carl Saalfeld, Diego Kauffmann-Guerrero, Oliver Illini, Albrecht Stenzinger, Achim Rittmeyer, Christoph Schubart, Sacha I. Rothschild, Christian Grohé, Urska Janzic, Cornelius F Waller, Tobias Raphael Overbeck, Laetitia Mauti, Susann Stephan-Falkenau, Marcel Wiesweg, Martin Faehling, Sabine Schmid, Waleed Kian, Marija Ivanović, Konstantinos Syrigos, Ronald Simon, Sabine Merkelbach-Bruse, Sascha Brückmann, Daniela Aust, Michael Thomas, Maximilian Hochmair, Amanda Tufman, Anna Rasokat, Petros Christopoulos, Martin Wermke, Marie-Elisabeth Leßmann, Lea Ruge, Kaija Minuth-Fuchs, Isabell Goetting, Katharina Schildknecht, Bastian Eul, Karin Armster, Rita Vesce, Hanna Schulte, Uwe Gerstenmaier, Rostyslav Lozynskyy, Sylvia Herold
|
Nature
Verified
Abstract Evidence on prognosis and optimal treatment for patients with advanced NSCLC harboring non-EML4-ALK fusions (rare ALK) remains limited. In a retrospective real-world cohort from 29 centers across six countries, overall survival (OS) appeared shorter in patients with rare ALK fusions (n = 51) compared with those with EML4-ALK fusions (n = 277; median 27 vs. 57 months, p = 0.08).
Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer - Nature Communications
Abstract Prostate cancer is a highly heterogeneous disease, driven by genomic and transcriptional changes that impact disease progression and metastatic potential. The interplay between clonal evolution, transcriptional plasticity, and tumour microenvironment is, however, poorly understood.
High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer | Prostate Cancer and Prostatic Diseases Original
Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery
Topical delivery, especially transdermal drug delivery, represents an effective alternative strategy to oral administration as it can bypass the first-pass effect in the liver [1]. Conventional formulations such as ointments, gels, and emulsions are commonly used for local drug delivery [2]. However, the presence of the stratum corneum (SC) and extracellular matrix (ECM) poses a dual barrier to efficient drug delivery.
An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9 - BMC Cancer
Analysis of breast cancers and normal breast tissues In this study, we reviewed four invasive breast carcinomas with POU2F3 expression that we had previously reported [13]. However, to investigate possible in situ components that were not included in previous tissue microarrays (TMAs), we used tumor full-face sections.
Mitochondrial mutations drive prostate cancer aggression
We collected 384 tumors from patients with localized prostate cancer, comprising 164 EOPCs and 220 late-onset prostate cancers (LOPC; Supplementary Data 1; Supplementary Fig. 1). The LOPC patients represented the three NCCN risk groups: 19 low-risk, 151 intermediate-risk, and 36 high-risk. The average sequencing depth of the mitochondrial genome was 13,577×, allowing extremely sensitive mutation detection.
Effect of misoprostol on patients with aspirin-exacerbated respiratory disease undergoing aspirin challenge and desensitization
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresFigure 1Modified nasal ketorolac and oral aspirin desensitization protocol. Ketorolac (60 mg/2 mL) was mixed with preservative-free normal saline (2.75 mL). Each spray delivers 1.26 mg of ketorolac solution.
Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single center study
Publication HistoryPublished online: May 24, 2017Accepted: May 3, 2017; Received in revised form: April 14, 2017; Received: June 24, 2016;
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ronald
Contact Ronald, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack